These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2162 related articles for article (PubMed ID: 17764220)

  • 21. Prospective assessment of microsatellite instability in gastrointestinal neoplasia in Ashkenazi and non-Ashkenazi Jews.
    Strul H; Liberman E; Kariv R; Gartner M; Kazanov D; Keidar A; Carmeli Y; Degani Y; Halpern Z; Arber N
    J Med; 2003; 34(1-6):139-48. PubMed ID: 17682319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Challenges in the diagnosis and management of Lynch Syndrome in an Indigenous family living in a remote West Australian community.
    Schofield L; Goldblatt J; Iacopetta B
    Rural Remote Health; 2011; 11(4):1836. PubMed ID: 22188021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study.
    Ryan NAJ; McMahon R; Tobi S; Snowsill T; Esquibel S; Wallace AJ; Bunstone S; Bowers N; Mosneag IE; Kitson SJ; O'Flynn H; Ramchander NC; Sivalingam VN; Frayling IM; Bolton J; McVey RJ; Evans DG; Crosbie EJ
    PLoS Med; 2020 Sep; 17(9):e1003263. PubMed ID: 32941469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of Lynch syndrome in consecutive patients with colorectal cancer.
    Green RC; Parfrey PS; Woods MO; Younghusband HB
    J Natl Cancer Inst; 2009 Mar; 101(5):331-40. PubMed ID: 19244167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing.
    Zhang L
    J Mol Diagn; 2008 Jul; 10(4):301-7. PubMed ID: 18556776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic DNA-based hMSH2 and hMLH1 mutation screening in 32 Eastern United States hereditary nonpolyposis colorectal cancer pedigrees.
    Weber TK; Conlon W; Petrelli NJ; Rodriguez-Bigas M; Keitz B; Pazik J; Farrell C; O'Malley L; Oshalim M; Abdo M; Anderson G; Stoler D; Yandell D
    Cancer Res; 1997 Sep; 57(17):3798-803. PubMed ID: 9288790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic testing among high-risk individuals in families with hereditary nonpolyposis colorectal cancer.
    Ponz de Leon M; Benatti P; Di Gregorio C; Pedroni M; Losi L; Genuardi M; Viel A; Fornasarig M; Lucci-Cordisco E; Anti M; Ponti G; Borghi F; Lamberti I; Roncucci L
    Br J Cancer; 2004 Feb; 90(4):882-7. PubMed ID: 14970868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of the mismatch-repair-deficient phenotype in colonic adenomas arising in HNPCC patients: results of a 5-year follow-up study.
    ; Müller A; Beckmann C; Westphal G; Bocker Edmonston T; Friedrichs N; Dietmaier W; Brasch FE; Kloor M; Poremba C; Keller G; Aust DE; Fass J; Büttner R; Becker H; Rüschoff J
    Int J Colorectal Dis; 2006 Oct; 21(7):632-41. PubMed ID: 16511680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficient detection of hereditary nonpolyposis colorectal cancer gene carriers by screening for tumor microsatellite instability before germline genetic testing.
    Terdiman JP; Gum JR; Conrad PG; Miller GA; Weinberg V; Crawley SC; Levin TR; Reeves C; Schmitt A; Hepburn M; Sleisenger MH; Kim YS
    Gastroenterology; 2001 Jan; 120(1):21-30. PubMed ID: 11208710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Feasibility of screening for Lynch syndrome among patients with colorectal cancer.
    Hampel H; Frankel WL; Martin E; Arnold M; Khanduja K; Kuebler P; Clendenning M; Sotamaa K; Prior T; Westman JA; Panescu J; Fix D; Lockman J; LaJeunesse J; Comeras I; de la Chapelle A
    J Clin Oncol; 2008 Dec; 26(35):5783-8. PubMed ID: 18809606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation.
    Stinton C; Jordan M; Fraser H; Auguste P; Court R; Al-Khudairy L; Madan J; Grammatopoulos D; Taylor-Phillips S
    Health Technol Assess; 2021 Jun; 25(42):1-216. PubMed ID: 34169821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strategies for screening for hereditary non-polyposis colorectal cancer.
    Loukola A; de la Chapelle A; Aaltonen LA
    J Med Genet; 1999 Nov; 36(11):819-22. PubMed ID: 10544224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of screening strategies for Lynch syndrome in patients with newly diagnosed endometrial cancer: a prospective cohort study in China.
    Chao X; Li L; Wu M; Ma S; Tan X; Zhong S; Bi Y; Lang J
    Cancer Commun (Lond); 2019 Jul; 39(1):42. PubMed ID: 31307542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing.
    Domingo E; Laiho P; Ollikainen M; Pinto M; Wang L; French AJ; Westra J; Frebourg T; Espín E; Armengol M; Hamelin R; Yamamoto H; Hofstra RM; Seruca R; Lindblom A; Peltomäki P; Thibodeau SN; Aaltonen LA; Schwartz S
    J Med Genet; 2004 Sep; 41(9):664-8. PubMed ID: 15342696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor testing to identify lynch syndrome in two Australian colorectal cancer cohorts.
    Buchanan DD; Clendenning M; Rosty C; Eriksen SV; Walsh MD; Walters RJ; Thibodeau SN; Stewart J; Preston S; Win AK; Flander L; Ouakrim DA; Macrae FA; Boussioutas A; Winship IM; Giles GG; Hopper JL; Southey MC; English D; Jenkins MA
    J Gastroenterol Hepatol; 2017 Feb; 32(2):427-438. PubMed ID: 27273229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The added value of PMS2 immunostaining in the diagnosis of hereditary nonpolyposis colorectal cancer.
    Halvarsson B; Lindblom A; Rambech E; Lagerstedt K; Nilbert M
    Fam Cancer; 2006; 5(4):353-8. PubMed ID: 16817031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Families at risk of colon cancer II. Hereditary nonpolyposis colorectal carcinoma].
    Hlavatý T; Lukác L; Duris I
    Vnitr Lek; 2004 Aug; 50(8):606-14. PubMed ID: 15521204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hereditary nonpolyposis colorectal carcinoma (HNPCC): surgical aspects].
    Möslein G
    Praxis (Bern 1994); 2001 Mar; 90(12):483-9. PubMed ID: 11324307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nationwide study of clinical and molecular features of hereditary non-polyposis colorectal cancer (HNPCC) in Latvia.
    Irmejs A; Borosenko V; Melbarde-Gorkusa I; Gardovskis A; Bitina M; Kurzawski G; Suchy J; Gorski B; Gardovskis J
    Anticancer Res; 2007; 27(1B):653-8. PubMed ID: 17348456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Refining the Amsterdam Criteria and Bethesda Guidelines: testing algorithms for the prediction of mismatch repair mutation status in the familial cancer clinic.
    Lipton LR; Johnson V; Cummings C; Fisher S; Risby P; Eftekhar Sadat AT; Cranston T; Izatt L; Sasieni P; Hodgson SV; Thomas HJ; Tomlinson IP
    J Clin Oncol; 2004 Dec; 22(24):4934-43. PubMed ID: 15611508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 109.